Merck & Co., Inc. vs Stanley Black & Decker, Inc. — how do they compare? Merck & Co., Inc. trades at $146.44 (market cap $351.28B), while Stanley Black & Decker, Inc. trades at $88.45 (market cap $13.47B). The key difference: Merck & Co., Inc. is far larger — about 26.1× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.77%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| MRK | SWK | |
|---|---|---|
Market Cap | $351.28B | $13.47B |
Volume | 7,969,665 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $156.43 | $104.00 |
52-Week Low | $82.49 | $62.12 |
Typical Hold Time | 98 Days | 62 Days |
Enterprise Value | $398.04B | $17.63B |
Dividend Yield | 2.39% | 3.77% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Stanley Black & Decker (SWK) trades at $88.49, up 0.2% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin of 4.06%. Valuation metrics appear reasonable with P/E of 21.8 and P/S of 0.89. Recent news highlights new product launches and dividend consistency as a Dividend King.
SWK presents a mixed outlook with strong brand positioning and margin improvement initiatives offset by technical weakness. The consensus price target of $93.00 suggests 5% upside potential, but investors face execution risks amid competitive pressures and ongoing operational challenges. The stock's dividend history provides income stability while awaiting fundamental improvements.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →